'20 years late': Docs on drug-maker's move to stop marketing OxyContin

Purdue Pharma, the producer of OxyContin, recently announced it would end physician-directed marketing of all opioids. The move is a step forward in efforts to control misuse and abuse of opioids in the U.S., but, according to physicians in Maine, it comes two decades too late.

"They're 20 years late to the game," said Noah Nesin, MD, a family physician and vice president of medical affairs at Penobscot Community Health Care in Bangor, Maine, to NPR.

A Feb. 13 story from NPR, Maine Public Radio and Kaiser Health News explores what impact, if any, the drug-maker’s change in approach will have on public health.

Read more at the link below:

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup